
Food Allergy - Pipeline Insight, 2024
Description
Food Allergy - Pipeline Insight, 2024
DelveInsight’s, “Food Allergies - Pipeline Insight, 2024,” report provides comprehensive insights about 30+ companies and 35+ pipeline drugs in Food Allergies pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Food Allergies: Overview
A food allergy occurs when the body’s immune system sees a certain food as harmful and reacts by causing symptoms. This is an allergic reaction. Foods that cause allergic reactions are allergens. The results of skin prick tests (SPT), IgE total and specific antibodies, and patient histories are not predictive of true food allergy, as they are not able to establish the causal and temporal relationship between the intake of the suspect food and the hypersensitivity reaction. The negative predictive accuracy of a skin prick test weal of < 3mm greater than the negative control is high, usually > 95%, and is strong evidence that the food may be consumed without severe, immediate food-allergic reactions. A positive SPT, even a weal of 3 mm or more, may be clinically irrelevant, as the patient may tolerate the ingested food. SPTs may also remain positive after the development of tolerance to the specific food. The foods to which an individual is allergic should be avoided, as therapeutic intervention (tertiary prevention) in patients with food allergy. It must strike a precautionary equilibrium between the demands of prohibitive measures against allergy care and quality of life. Hypersensitivity reactions are often treated with medications. . Epinephrine is the only medication that is effective for the treatment of anaphylaxis. Additional medicatioons include H1 and H2 antihistamines, corticosteroids, and prostaglandin synthetase inhibitors.
""Food Allergies - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Food Allergies pipeline landscape is provided which includes the disease overview and Food Allergies treatment guidelines. The assessment part of the report embraces, in depth Food Allergies commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Food Allergies collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Food Allergies.
- In the coming years, the Food Allergies market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
- The companies and academics that are working to assess challenges and seek opportunities that could influence Food Allergies R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
- A detailed portfolio of major pharma players who are involved in fueling the Food Allergies treatment market. Several potential therapies for Food Allergies are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Food Allergies market size in the coming years.
- Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Food Allergies) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
This segment of the Food Allergies report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Food Allergies Emerging Drugs
- Viaskin Peanut: DBV technologies
- Omalizumab: Genentech
- Dupilumab: Regeneron Pharmaceuticals
- ADP101: Alladapt Immunotherapeutics
Further product details are provided in the report……..
Food Allergies: Therapeutic Assessment
This segment of the report provides insights about the different Food Allergies drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Food Allergies
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Inhalation
- Inhalation/Intravenous/Oral
- Intranasal
- Intravenous
- Intravenous/ Subcutaneous
- NA
- Oral
- Oral/intranasal/subcutaneous
- Parenteral
- Subcutaneous
- Molecule Type
- Antibody
- Antisense oligonucleotides
- Immunotherapy
- Monoclonal antibody
- Peptides
- Protein
- Recombinant protein
- Small molecule
- Stem Cell
- Vaccine
- Product Type
Food Allergies: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Food Allergies therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Food Allergies drugs.
Food Allergies Report Insights
- Food Allergies Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Food Allergies drugs?
- How many Food Allergies drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Food Allergies?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Food Allergies therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Food Allergies and their status?
- What are the key designations that have been granted to the emerging drugs?
- DBV technologies
- Genentech
- Camallergy
- Novartis Pharmaceuticals
- Prota Therapeutics
- Regeneron Pharmaceuticals
- Astrazeneca
- DBV Technologies
- Aimmune Therapeutics (Nestlé)
- InnoUp Farma
- Cour Pharmaceuticals
- Alladapt Immunotherapeutics
- Vedanta Biosciences
- Siolta Therapeutics
- Aravax
- Intrommune Therapeutics
- GI Innovation
- HAL Allergy
- Xencor
- BlueWillow Biologics
- Mabylon
- Allergy Therapeutics
- ASIT biotech
- ALK
- ASIT biotech
- Viaskin Peanut
- Omalizumab
- CA002
- Ligelizumab
- PRT100
- Dupilumab
- Acalabrutinib
- DBV135 (Viaskin Milk)
- AR201
- INP20
- CNP-201
- ADP101
- VE 416
- STMC-103H
- PVX108
- INT301
- GI 301
- HAL-MPE1
- AIMab 7195
- Peanut Allergy Therapeutic Vaccine
- Allergy Programs: Peanut Allergy
- VLP Peanut
- pnt-ASIT+TM
- Peanut program
- Research Programme
Table of Contents
90 Pages
- Introduction
- Executive Summary
- Food Allergies: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Food Allergies – DelveInsight’s Analytical Perspective
- Late Stage Products (Preregistration)
- Comparative Analysis
- Viaskin Peanut: DBV technologies
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- Dupilumab: Regeneron
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I/II)
- Comparative Analysis
- ADP101: Alladapt Immunotherapeutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Research programme : antiallergy therapeutics: IgGenix
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Food Allergies Key Companies
- Food Allergies Key Products
- Food Allergies- Unmet Needs
- Food Allergies- Market Drivers and Barriers
- Food Allergies- Future Perspectives and Conclusion
- Food Allergies Analyst Views
- Food Allergies Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.